Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,

Miriam Treggiari, Margaret Rosenfeld, Nicole Mayer-Hamblett, George Retsch-Bogart, Ronald L. Gibson, Judy Williams, Julia Emerson, Richard A. Kronmal, Bonnie W. Ramsey

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Background: The primary cause of morbidity and mortality in patients with cystic fibrosis (CF) is progressive obstructive pulmonary disease due to chronic endobronchial infection, particularly with Pseudomonas aeruginosa (Pa). Risk factors for and clinical impact of early Pa infection in young CF patients are less well understood. Purpose: The present studies are designed to evaluate risk factors and outcomes associated with early Pa acquisition, and the benefits and harms of four anti-pseudomonal treatment regimens in young CF patients initiated after the first Pa positive respiratory culture. Methods: The Early Pseudomonas Infection Control (EPIC) program consists of two studies, a randomized multicenter trial in CF patients ages 1-12 years at first isolation of Pa from a respiratory culture, and a longitudinal cohort study enrolling Pa-negative patients. Using a factorial design, trial participants are assigned for 18 months to either anti-pseudomonal treatment on a scheduled quarterly basis (cycled therapy) or based on recovery of Pa from quarterly respiratory cultures (culture-based therapy). The study drugs include inhaled tobramycin (300 mg BID) for 28 days, combined with either oral ciprofloxacin (15-20 mg/kg BID) or oral placebo for 14 days. The primary endpoints of the trial are the time to pulmonary exacerbation requiring IV antibiotics or hospitalization for respiratory symptoms, and the proportion of patients with new Pa-positive respiratory cultures during the study. The broad goals of the observational study are to describe the risk factors and outcomes associated with early acquisition of Pa. 306 patients were randomized in the clinical trial and 1787 were enrolled in the cohort study. Conclusions: These companion studies will provide valuable epidemiological and microbiological information on early CF lung disease and Pa acquisition, and safety and clinical efficacy data on anti-pseudomonal treatment strategies for early Pa infections in the airways of young children with CF.

Original languageEnglish (US)
Pages (from-to)256-268
Number of pages13
JournalContemporary Clinical Trials
Volume30
Issue number3
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Pseudomonas Infections
Infection Control
Cystic Fibrosis
Pseudomonas aeruginosa
Observational Studies
Clinical Trials
Clinical Studies
Cohort Studies
Obstructive Lung Diseases
Therapeutics
Tobramycin
Ciprofloxacin
Lung Diseases
Multicenter Studies
Longitudinal Studies
Hospitalization
Randomized Controlled Trials
Placebos

Keywords

  • Antimicrobials
  • Ciprofloxacin
  • Clinical trial
  • Inhaled tobramycin
  • Mucoviscidosis
  • Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Early anti-pseudomonal acquisition in young patients with cystic fibrosis : Rationale and design of the EPIC clinical trial and observational study, / Treggiari, Miriam; Rosenfeld, Margaret; Mayer-Hamblett, Nicole; Retsch-Bogart, George; Gibson, Ronald L.; Williams, Judy; Emerson, Julia; Kronmal, Richard A.; Ramsey, Bonnie W.

In: Contemporary Clinical Trials, Vol. 30, No. 3, 05.2009, p. 256-268.

Research output: Contribution to journalArticle

Treggiari, M, Rosenfeld, M, Mayer-Hamblett, N, Retsch-Bogart, G, Gibson, RL, Williams, J, Emerson, J, Kronmal, RA & Ramsey, BW 2009, 'Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,', Contemporary Clinical Trials, vol. 30, no. 3, pp. 256-268. https://doi.org/10.1016/j.cct.2009.01.003
Treggiari, Miriam ; Rosenfeld, Margaret ; Mayer-Hamblett, Nicole ; Retsch-Bogart, George ; Gibson, Ronald L. ; Williams, Judy ; Emerson, Julia ; Kronmal, Richard A. ; Ramsey, Bonnie W. / Early anti-pseudomonal acquisition in young patients with cystic fibrosis : Rationale and design of the EPIC clinical trial and observational study,. In: Contemporary Clinical Trials. 2009 ; Vol. 30, No. 3. pp. 256-268.
@article{0fc0ff8f4ddd485aaffccac99149993a,
title = "Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,",
abstract = "Background: The primary cause of morbidity and mortality in patients with cystic fibrosis (CF) is progressive obstructive pulmonary disease due to chronic endobronchial infection, particularly with Pseudomonas aeruginosa (Pa). Risk factors for and clinical impact of early Pa infection in young CF patients are less well understood. Purpose: The present studies are designed to evaluate risk factors and outcomes associated with early Pa acquisition, and the benefits and harms of four anti-pseudomonal treatment regimens in young CF patients initiated after the first Pa positive respiratory culture. Methods: The Early Pseudomonas Infection Control (EPIC) program consists of two studies, a randomized multicenter trial in CF patients ages 1-12 years at first isolation of Pa from a respiratory culture, and a longitudinal cohort study enrolling Pa-negative patients. Using a factorial design, trial participants are assigned for 18 months to either anti-pseudomonal treatment on a scheduled quarterly basis (cycled therapy) or based on recovery of Pa from quarterly respiratory cultures (culture-based therapy). The study drugs include inhaled tobramycin (300 mg BID) for 28 days, combined with either oral ciprofloxacin (15-20 mg/kg BID) or oral placebo for 14 days. The primary endpoints of the trial are the time to pulmonary exacerbation requiring IV antibiotics or hospitalization for respiratory symptoms, and the proportion of patients with new Pa-positive respiratory cultures during the study. The broad goals of the observational study are to describe the risk factors and outcomes associated with early acquisition of Pa. 306 patients were randomized in the clinical trial and 1787 were enrolled in the cohort study. Conclusions: These companion studies will provide valuable epidemiological and microbiological information on early CF lung disease and Pa acquisition, and safety and clinical efficacy data on anti-pseudomonal treatment strategies for early Pa infections in the airways of young children with CF.",
keywords = "Antimicrobials, Ciprofloxacin, Clinical trial, Inhaled tobramycin, Mucoviscidosis, Pseudomonas aeruginosa",
author = "Miriam Treggiari and Margaret Rosenfeld and Nicole Mayer-Hamblett and George Retsch-Bogart and Gibson, {Ronald L.} and Judy Williams and Julia Emerson and Kronmal, {Richard A.} and Ramsey, {Bonnie W.}",
year = "2009",
month = "5",
doi = "10.1016/j.cct.2009.01.003",
language = "English (US)",
volume = "30",
pages = "256--268",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Early anti-pseudomonal acquisition in young patients with cystic fibrosis

T2 - Rationale and design of the EPIC clinical trial and observational study,

AU - Treggiari, Miriam

AU - Rosenfeld, Margaret

AU - Mayer-Hamblett, Nicole

AU - Retsch-Bogart, George

AU - Gibson, Ronald L.

AU - Williams, Judy

AU - Emerson, Julia

AU - Kronmal, Richard A.

AU - Ramsey, Bonnie W.

PY - 2009/5

Y1 - 2009/5

N2 - Background: The primary cause of morbidity and mortality in patients with cystic fibrosis (CF) is progressive obstructive pulmonary disease due to chronic endobronchial infection, particularly with Pseudomonas aeruginosa (Pa). Risk factors for and clinical impact of early Pa infection in young CF patients are less well understood. Purpose: The present studies are designed to evaluate risk factors and outcomes associated with early Pa acquisition, and the benefits and harms of four anti-pseudomonal treatment regimens in young CF patients initiated after the first Pa positive respiratory culture. Methods: The Early Pseudomonas Infection Control (EPIC) program consists of two studies, a randomized multicenter trial in CF patients ages 1-12 years at first isolation of Pa from a respiratory culture, and a longitudinal cohort study enrolling Pa-negative patients. Using a factorial design, trial participants are assigned for 18 months to either anti-pseudomonal treatment on a scheduled quarterly basis (cycled therapy) or based on recovery of Pa from quarterly respiratory cultures (culture-based therapy). The study drugs include inhaled tobramycin (300 mg BID) for 28 days, combined with either oral ciprofloxacin (15-20 mg/kg BID) or oral placebo for 14 days. The primary endpoints of the trial are the time to pulmonary exacerbation requiring IV antibiotics or hospitalization for respiratory symptoms, and the proportion of patients with new Pa-positive respiratory cultures during the study. The broad goals of the observational study are to describe the risk factors and outcomes associated with early acquisition of Pa. 306 patients were randomized in the clinical trial and 1787 were enrolled in the cohort study. Conclusions: These companion studies will provide valuable epidemiological and microbiological information on early CF lung disease and Pa acquisition, and safety and clinical efficacy data on anti-pseudomonal treatment strategies for early Pa infections in the airways of young children with CF.

AB - Background: The primary cause of morbidity and mortality in patients with cystic fibrosis (CF) is progressive obstructive pulmonary disease due to chronic endobronchial infection, particularly with Pseudomonas aeruginosa (Pa). Risk factors for and clinical impact of early Pa infection in young CF patients are less well understood. Purpose: The present studies are designed to evaluate risk factors and outcomes associated with early Pa acquisition, and the benefits and harms of four anti-pseudomonal treatment regimens in young CF patients initiated after the first Pa positive respiratory culture. Methods: The Early Pseudomonas Infection Control (EPIC) program consists of two studies, a randomized multicenter trial in CF patients ages 1-12 years at first isolation of Pa from a respiratory culture, and a longitudinal cohort study enrolling Pa-negative patients. Using a factorial design, trial participants are assigned for 18 months to either anti-pseudomonal treatment on a scheduled quarterly basis (cycled therapy) or based on recovery of Pa from quarterly respiratory cultures (culture-based therapy). The study drugs include inhaled tobramycin (300 mg BID) for 28 days, combined with either oral ciprofloxacin (15-20 mg/kg BID) or oral placebo for 14 days. The primary endpoints of the trial are the time to pulmonary exacerbation requiring IV antibiotics or hospitalization for respiratory symptoms, and the proportion of patients with new Pa-positive respiratory cultures during the study. The broad goals of the observational study are to describe the risk factors and outcomes associated with early acquisition of Pa. 306 patients were randomized in the clinical trial and 1787 were enrolled in the cohort study. Conclusions: These companion studies will provide valuable epidemiological and microbiological information on early CF lung disease and Pa acquisition, and safety and clinical efficacy data on anti-pseudomonal treatment strategies for early Pa infections in the airways of young children with CF.

KW - Antimicrobials

KW - Ciprofloxacin

KW - Clinical trial

KW - Inhaled tobramycin

KW - Mucoviscidosis

KW - Pseudomonas aeruginosa

UR - http://www.scopus.com/inward/record.url?scp=67349204479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349204479&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2009.01.003

DO - 10.1016/j.cct.2009.01.003

M3 - Article

C2 - 19470318

AN - SCOPUS:67349204479

VL - 30

SP - 256

EP - 268

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

IS - 3

ER -